Salma Jabbour, MD, on Future Trials in Stage III NSCLC
CancerNetwork® sat down with Salma Jabbour, MD, of Rutgers Cancer Institute, at 2021 ASCO to talk about what she believed was the most interesting and impactful study to come out of the meeting.
At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Salma Jabbour, MD, to discuss her thoughts about the phase 2 KEYNOTE-799 trial (NCT03631784). This study examined pembrolizumab (Keytruda) in combination with platinum-doublet chemotherapy and radiation in patients with unresectable, stage III non–small cell lung cancer (NSCLC).
Results of the trial indicated that the treatment regimen for this population of patients demonstrated promising antitumor activity across patient subgroups regardless of PD-L1 expression and tumor histology. In a group of patients with mixed histology who were treated with pembrolizumab plus carboplatin/paclitaxel, the overall response rate was 70.5% (95% CI, 61.2%-78.8%), with more than three-quarters of patients having a response duration longer than 1 year.
Transcript:
I’m, excited about KEYNOTE-799. I do think that this will open the door for many future trials, and much excitement in the stage III setting. I am excited to continue to hear further results about stage III lung cancers.
Reference
Jabbour SK, KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.
